Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma
Marostica E, Barber R, Denize T, et al.
Clin Cancer Res. 2021 May 15;27(10):2868-2878.
Histopathology evaluation is the gold standard for diagnosing clear cell (ccRCC), papillary, and chromophobe renal cell carcinoma (RCC). However, interrater variability has been reported, and the whole-slide histopathology images likely contain underutilized biological signals predictive of genomic profiles.
To address this knowledge gap, we obtained whole-slide histopathology images and demographic, genomic, and clinical data from The Cancer Genome Atlas, the Clinical Proteomic Tumor Analysis Consortium, and Brigham and Women’s Hospital (Boston, MA) to develop computational methods for integrating data analyses. Leveraging these large and diverse datasets, we developed fully automated convolutional neural networks to diagnose renal cancers and connect quantitative pathology patterns with patients’ genomic profiles and prognoses.
Our deep convolutional neural networks successfully detected malignancy (AUC in the independent validation cohort: 0.964-0.985), diagnosed RCC histologic subtypes (independent validation AUCs of the best models: 0.953-0.993), and predicted stage I ccRCC patients’ survival outcomes (log-rank test P = 0.02). Our machine learning approaches further identified histopathology image features indicative of copy-number alterations (AUC > 0.7 in multiple genes in patients with ccRCC) and tumor mutation burden.
Our results suggest that convolutional neural networks can extract histologic signals predictive of patients’ diagnoses, prognoses, and genomic variations of clinical importance. Our approaches can systematically identify previously unknown relations among diverse data modalities.